Miricorilant
Metabolic Dysfunction-Associated Steatohepatitis
Explore 128 assets in Metabolic Dysfunction-Associated Steatohepatitis →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Corcept Therapeutics
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07553663CT.gov Evaluating the Pharmacokinetics and Safety of Miricorilant | — | Recruiting | — | — | — |
NCT06947304CT.gov Evaluation of Miricorilant on Liver Fat in Patients With MASLD | — | Recruiting | — | — | — |
NCT06108219CT.gov A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | — | Active Not Recruiting | — | — | — |
NCT05712265CT.gov Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | — | Completed | — | — | — |
NCT05553470CT.gov Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | — | Completed | — | — | — |
NCT05117489CT.gov A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT03823703CT.gov Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatohepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Miricorilant (this asset) | Corcept Therapeutics | P2 | B · 60 |
| Resmetirom | City University of New York | P4 | BBB |
| Pentoxifylline | Al-Azhar University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Firsocostat | Gilead Sciences | P2 | BBB |
| Montelukast | Tanta University | P4 | BBB |
| Alpha Tocopherol | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Rosuvastatin | Beni-Suef University | P4 | BBB |
| Ezetimibe | University of Palermo | P4 | BBB |
+42 more in the Metabolic Dysfunction-Associated Steatohepatitis cohort
Other indications for Miricorilant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P2 | BB · 69 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Miricorilant in Metabolic Dysfunction-Associated Steatohepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/miricorilant-metabolic-dysfunction-associated-steatohepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →